<DOC>
	<DOC>NCT00992381</DOC>
	<brief_summary>The purpose of this study is to determine whether the absorption of naproxen from the PN 400 combination (Naprosyn and Esomeprazole) tablets is similar to that from the naproxen tablets (NaprosynÂ®), which are currently sold in Australia.</brief_summary>
	<brief_title>Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone</brief_title>
	<detailed_description />
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Subjects must have a body weight greater than 50 kg and BMI within the range 1830(inclusive). Subjects must be in good health, as assessed during prestudy medical examination and by review of screening results Subjects must understand the procedures involved and agree to participate in the study by giving fully informed, written consent Significant intercurrent disease of any type, in particular liver, kidney, cardiovascular disease, any form of diabetes or significant gastrointestinal disorder which could affect drug absorption, or any history of gastric or duodenal ulceration. Ingestion of any naproxen, omeprazole, esomeprazole or related drugs prior to the recruitment interview, such that these drugs will have been ingested in the 4 weeks prior to the day set for the first Period 1 dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>GI Pain</keyword>
	<keyword>healthy participants</keyword>
	<keyword>Safety</keyword>
	<keyword>bioavailability</keyword>
</DOC>